Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06401642 · ClinicalTrials.gov registry record · Phase 4
Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
A Phase 4 study of Migraine, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT06401642: Recruiting Phase 4 study of Migraine, sponsored by Mayo Clinic.
NCT06401642 is a Phase 4 study of Migraine that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 200 participants, below the 356-participant average among 102 other Migraine trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06401642, a Phase 4 study of Migraine, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
Zavegepant (Zavzpret) is approved for the acute treatment of migraine with or without aura in the US. The purpose of this study is to investigate the effectiveness and tolerability of zavegepant for the acute treatment of migraine attacks amongst participants who are using calcitonin gene-related peptide (CGRP) migraine preventive treatments.
Primary Outcome
Percentage of participants who have meaningful headache relief within 2 hours of administering zavegepant
Conditions Studied
Interventions
- DRUG Zavegepant
Study Locations (1)
Arizona
- Mayo Clinic in Arizona - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-03-22 |
| Est. Completion | 2027-03 |
| Phase | Phase 4 |
What NCT06401642 shows while recruiting
NCT06401642 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 356-participant average among 102 other Migraine trials with a reported enrollment target (44% lower).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which Zavegepant is the first listed.
NCT06401642 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT06401642 about?
NCT06401642 is a clinical study titled "Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications". Zavegepant (Zavzpret) is approved for the acute treatment of migraine with or without aura in the US. The purpose of this study is to investigate the effectiveness and tolerability of zavegepant for the acute treatment of migraine attacks amongst participants who are using calcitonin gene-related pe...
What is the current status of trial NCT06401642?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2024-03-22. Estimated completion is 2027-03.
What conditions does trial NCT06401642 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT06401642?
The interventions under investigation include: Zavegepant (DRUG).
Who is sponsoring clinical trial NCT06401642?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06401642 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06401642's enrollment target sits among peer trials
200 38th of 102 higher than 62 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
RECRUITING · Phase 4
-
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
RECRUITING · Phase 4
-
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
RECRUITING · Phase 4
-
Nerivio Efficacy Under High-Frequency Use
ACTIVE NOT RECRUITING · Phase 4
-
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
ACTIVE NOT RECRUITING · Phase 4
-
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI